1-氯-4-(2,2-二甲基丙氧基)苯 | 2180-28-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 1-氯-4-(2,2-二甲基丙氧基)苯
• 英文名称: p-neopentoxychlorobenzene
• 英文别名: 2-(4-Chlor-phenoxymethyl)-2-methyl-propan；1-Chloro-4-(2,2-dimethylpropoxy)benzene
• CAS: 2180-28-1
• 化学式: C₁₁H₁₅ClO
• 分子量: 198.692
• InChiKey: AHWFSQRFJJHPJP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2909309090

反应信息

• 作为产物：
  描述：

  2-(4-Chlor-phenoxymethyl)-2-methyl-1,3-bis-tosyloxy-propan 在 lithium aluminium tetrahydride 作用下， 生成 1-氯-4-(2,2-二甲基丙氧基)苯
  参考文献：
  名称：

  Seyden-Penne,J. et al., Bulletin de la Societe Chimique de France, 1965, p. 700 - 704

  摘要：

  DOI：

文献信息

• Electronic Dependence of C−O Reductive Elimination from Palladium (Aryl)neopentoxide Complexes
  作者：Ross A. Widenhoefer、Stephen L. Buchwald

  DOI：10.1021/ja9806581

  日期：1998.7.1

  decomposition of 1b−f obeyed first-order kinetics, and the rate of reductive elimination decreased in the order o-NO2 > p-NO2 > p-CHO > p-COPh > o-CN. Conversely, thermal decomposition of the related derivatives [P−P]Pd(Ar)OCH2CMe3 [P−P = Tol-BINAP or BINAP; Ar = p-C6H4Cl (1g), m-C6H4NO2 (1h), m-C6H4CN (1i)] which did not possess a resonance stabilizing group on the palladium-bound aryl group led to no detectable

  钯（芳基）新五氧化物络合物的热分解 [P-P]Pd(Ar)OCH2CMe3 [P-P = Tol-BINAP 或 BINAP；Ar = p-C6H4CHO (1b), p-C6H4COPh (1c), p-C6H4NO2 (1d), o-C6H4NO2 (1e), o-C6H4CN (1f)] 在钯结合的芳基上具有适合于离域的取代基负电荷导致芳醚的定量 (≥95%) 形成而没有可检测的 β-氢化物消除。1b-f 的热分解服从一级动力学，还原消除速率按 o-NO2 > p-NO2 > p-CHO > p-COPh > o-CN 的顺序降低。相反，相关衍生物的热分解 [P-P]Pd(Ar)OCH2CMe3 [P-P = Tol-BINAP 或 BINAP；Ar = p-C6H4Cl (1g), m-C6H4NO2 (1h), m-C6H4CN (1i)] 在钯结合的芳基上不具有共振稳定基团，导致无法检测到芳醚的形成。
• GLYCINE TRANSPORTER INHIBITING SUBSTANCES
  申请人：Yasuhara Akito

  公开号：US20120010414A1

  公开（公告）日：2012-01-12

  The present invention aims to provide novel compounds of formula [I] or pharmaceutically acceptable salts thereof that are based on a glycine uptake inhibiting action and which are useful in the prevention or treatment of such diseases as schizophrenia, Alzheimer's disease, cognitive dysfunction, dementia, anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsory disorder, social anxiety disorder, posttraumatic stress disorder, specific phobia, acute stress disorder, etc.), depression, drug addiction, spasm, tremor, and sleep disorder:

  本发明旨在提供基于甘氨酸摄取抑制作用的新型化合物，其化学式为[I]或其药学上可接受的盐，可用于预防或治疗精神分裂症、阿尔茨海默病、认知功能障碍、痴呆、焦虑障碍（广泛性焦虑障碍、恐慌障碍、强迫性障碍、社交焦虑障碍、创伤后应激障碍、特定恐惧症、急性应激障碍等）、抑郁症、药物成瘾、痉挛、震颤和睡眠障碍等疾病的治疗。
• Novel piperazines, pharmaceutical compositions and methods of use thereof
  申请人：Clark B. Roger

  公开号：US20080051415A1

  公开（公告）日：2008-02-28

  Disclosed are novel piperazine derivatives that act as agonists of the α7 nAChR. Also disclosed are pharmaceutical compositions, methods of treating inflammatory conditions, methods of treating CNS disorders, methods for inhibiting cytokine release from mammalian cells and methods for the preparation of the novel compounds.

  本发明涉及一种新的哌嗪衍生物，其作为α7 nAChR的激动剂。同时还揭示了制药组合物，治疗炎症疾病的方法，治疗中枢神经系统疾病的方法，抑制哺乳动物细胞细胞因子释放的方法以及制备新化合物的方法。
• Crf Receptor Antagonists and Methods Relating Thereto
  申请人：Luo Zhiyong

  公开号：US20070287705A1

  公开（公告）日：2007-12-13

  CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm blooded animals, such as stroke. The CRF receptor antagonists of this invention have the following structure (I), including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, Y, Ar, and het are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.

  本发明揭示了CRF受体拮抗剂，其在治疗各种疾病中具有用途，包括治疗温血动物中CRF分泌过多表现的疾病，例如中风。本发明的CRF受体拮抗剂具有以下结构（I），包括立体异构体、前药和其药物可接受的盐，其中R1、R2、R3、Y、Ar和het的定义如下。本发明还揭示了含有CRF受体拮抗剂和药物可接受载体的组合物，以及使用它们的方法。
• Imine Compound
  申请人：Saito Shiuji

  公开号：US20080312435A1

  公开（公告）日：2008-12-18

  An imine compound represented by the formula: wherein A represents a heterocyclic group; R 1 , R 2 , an R 3 each represent a hydrogen atom, a halogen atom, a C 1-10 alkyl group optionally substituted with an aryl group(s) substituted with a halogen atom(s), a C 3-10 cycloalkyl group, a C 1-6 haloalkyl group, a C 1-10 alkoxy group, etc.; R 4 represents an optionally substituted C 1-10 alkyl, C 2-6 alkenyl, or aryl group; R 5 represents a hydrogen atom, a C 1-10 alkoxy group, a C 1-6 haloalkyl group, an optionally substituted C 1-10 alkyl or C 2-6 alkenyl group, an optionally substituted aryl or heterocyclic group, etc.; W represents —CO—, —CO—CO—, —CO—NH—, —CS—NH—, or —SO 2 —, or a cannabinoid-receptor agonist comprising said imine compound as an active ingredient. The imine compound of the present invention has a cannabinoid-receptor agonist effect, and is useful as a therapeutic or prophylactic drug for pains and autoimmune diseases.

  一种以以下式表示的亚胺化合物：其中A代表杂环基团；R1、R2和R3分别表示氢原子、卤素原子、C1-10烷基，该烷基可选地取代有芳基，所述芳基取代有卤素原子，C3-10环烷基，C1-6卤代烷基，C1-10烷氧基等；R4表示可选地取代的C1-10烷基，C2-6烯基或芳基；R5表示氢原子，C1-10烷氧基，C1-6卤代烷基，可选地取代的C1-10烷基或C2-6烯基，可选地取代的芳基或杂环基团等；W表示—CO—，—CO—CO—，—CO—NH—，—CS—NH—或—SO2—，或以该亚胺化合物为活性成分的大麻素受体激动剂。本发明的亚胺化合物具有大麻素受体激动剂作用，可用作治疗或预防疼痛和自身免疫性疾病的药物。